Innovation Package

Experiment: A salivary test to detect endometriosis

Publié le 18 février 2025 - Directorate for Legal and Administrative Information (Prime Minister)

A salivary test to detect endometriosis is now managed by the Social Security: the Endotest® in a study promoted by the Ziwig business. That's what an order in council says Official Journal February 11, 2025. This breakthrough marks an important step in the fight against this inflammatory gynecological disease, which affects about 1 in 10 women in France.

Availability and accessibility

The saliva test, developed by the French business Ziwig, is currently available in 80 hospitals across the country. The High Authority for Health has recognized the value of this test and has given its opinion in favor of taking it over under the innovation package.

FYI  

The innovation package consists of a early and derogatory management of medical devices and innovative acts, subject to clinical and possibly medico-economic studies to provide the missing data.

Practical information

To benefit from this test, patients over 18 years of age must go to one of the 80 hospitals participating in the study. The test is noninvasive and provides results within 10 days, allowing rapid diagnosis even before endometriosis is seen on imaging studies. This new device aims to reduce diagnostic wandering, which can currently last between 7 and 10 years.

FYI  

The list of health establishments for which the sickness insurance shall pay the lump sum is specified in annex to the order of 6 february 2025.

Amount of the support package

The amount of the Endotest medical device per patient support fee®, including the cost of the procedure and associated hospitalization costs, is EUR 839. Where appropriate, practitioners who practice on a liberal basis negotiate the billing of their fees with health care institutions.

Please note

The Endotest medical device®, used for the diagnosis of endometriosis, will be financially supported for a period of 3 years from the start of the patient study.

Warning  

The total number of patients eligible for treatment is set at 25,000, of which 2,500 patients are in the study and 22,500 additional patients are not included in the study.

Additional topics

Agenda

See all due dates